These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23318502)

  • 1. The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.
    Simonsen L; Holst JJ; Madsen K; Deacon CF
    Regul Pept; 2013 Feb; 181():17-21. PubMed ID: 23318502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.
    Simonsen L; Holst JJ; Deacon CF
    Diabetologia; 2006 Apr; 49(4):706-12. PubMed ID: 16447056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional association of the N-terminal residues with the central region in glucagon-related peptides.
    Patterson JT; Day JW; Gelfanov VM; DiMarchi RD
    J Pept Sci; 2011 Oct; 17(10):659-66. PubMed ID: 21661079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
    Li Y; Zheng X; Tang L; Xu W; Gong M
    Peptides; 2011 Jun; 32(6):1303-12. PubMed ID: 21515323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV.
    Hansen L; Hare KJ; Hartmann B; Deacon CF; Ugleholdt RK; Plamboeck A; Holst JJ
    Regul Pept; 2007 Feb; 138(2-3):126-32. PubMed ID: 17107718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.
    Yi J; Warunek D; Craft D
    PLoS One; 2015; 10(7):e0134427. PubMed ID: 26222180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
    Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
    Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Yannaing S; Kuwayama H
    Domest Anim Endocrinol; 2013 Feb; 44(2):70-80. PubMed ID: 23122871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
    Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility.
    Lee JG; Ryu JH; Kim SM; Park MY; Kim SH; Shin YG; Sohn JW; Kim HH; Park ZY; Seong JY; Kim JI
    Biochem Pharmacol; 2018 May; 151():59-68. PubMed ID: 29522713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK
    Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
    Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
    J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.
    Doyle ME; Theodorakis MJ; Holloway HW; Bernier M; Greig NH; Egan JM
    Regul Pept; 2003 Jul; 114(2-3):153-8. PubMed ID: 12832104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
    Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
    Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.